vs
AbCellera Biologics Inc.（ABCL）与硕腾（ZTS）财务数据对比。点击上方公司名可切换其他公司
硕腾的季度营收约是AbCellera Biologics Inc.的53.2倍（$2.4B vs $44.9M）。硕腾净利率更高（25.3% vs -19.9%，领先45.2%）。AbCellera Biologics Inc.同比增速更快（788.4% vs 3.0%）。硕腾自由现金流更多（$732.0M vs $-44.6M）。过去两年AbCellera Biologics Inc.的营收复合增速更高（112.3% vs 4.4%）
AbCellera Biologics是一家总部位于不列颠哥伦比亚省温哥华的生物科技企业，核心业务是探索与开发抗体治疗药物。该公司凭借 proprietary 技术平台可在60天内开发出医疗应对方案，其单细胞筛选技术平台最早诞生于不列颠哥伦比亚大学，还曾作为核心力量参与美国国防高级研究计划局的大流行预防平台项目。
硕腾是全球规模最大的动物保健制药企业，专注于宠物与家畜用药品、疫苗的研发和生产，前身为制药巨头辉瑞旗下的动物保健业务板块，辉瑞剥离多数股权后成为完全独立的企业。目前公司产品直销约45个国家，在全球超过100个国家和地区销售，海外业务占总营收的50%左右。
ABCL vs ZTS — 直观对比
营收规模更大
ZTS
是对方的53.2倍
$44.9M
营收增速更快
ABCL
高出785.4%
3.0%
净利率更高
ZTS
高出45.2%
-19.9%
自由现金流更多
ZTS
多$776.6M
$-44.6M
两年增速更快
ABCL
近两年复合增速
4.4%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $44.9M | $2.4B |
| 净利润 | $-8.9M | $603.0M |
| 毛利率 | — | 70.2% |
| 营业利润率 | -63.7% | 31.9% |
| 净利率 | -19.9% | 25.3% |
| 营收同比 | 788.4% | 3.0% |
| 净利润同比 | 73.9% | 3.8% |
| 每股收益（稀释后） | $-0.03 | $1.37 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ABCLZTS
| Q4 25 | $44.9M | $2.4B | ||
| Q3 25 | $9.0M | $2.4B | ||
| Q2 25 | $17.1M | $2.5B | ||
| Q1 25 | $4.2M | $2.2B | ||
| Q4 24 | $5.0M | $2.3B | ||
| Q3 24 | $6.5M | $2.4B | ||
| Q2 24 | $7.3M | $2.4B | ||
| Q1 24 | $10.0M | $2.2B |
净利润ABCLZTS
| Q4 25 | $-8.9M | $603.0M | ||
| Q3 25 | $-57.1M | $721.0M | ||
| Q2 25 | $-34.7M | $718.0M | ||
| Q1 25 | $-45.6M | $631.0M | ||
| Q4 24 | $-34.2M | $581.0M | ||
| Q3 24 | $-51.1M | $682.0M | ||
| Q2 24 | $-36.9M | $624.0M | ||
| Q1 24 | $-40.6M | $599.0M |
毛利率ABCLZTS
| Q4 25 | — | 70.2% | ||
| Q3 25 | — | 71.5% | ||
| Q2 25 | — | 73.6% | ||
| Q1 25 | — | 72.0% | ||
| Q4 24 | — | 69.5% | ||
| Q3 24 | — | 70.6% | ||
| Q2 24 | — | 71.7% | ||
| Q1 24 | — | 70.6% |
营业利润率ABCLZTS
| Q4 25 | -63.7% | 31.9% | ||
| Q3 25 | -851.8% | 37.0% | ||
| Q2 25 | -290.2% | 36.7% | ||
| Q1 25 | -1479.6% | 36.5% | ||
| Q4 24 | -1441.0% | 31.6% | ||
| Q3 24 | -1439.4% | 36.6% | ||
| Q2 24 | -1276.2% | 33.0% | ||
| Q1 24 | -551.5% | 34.1% |
净利率ABCLZTS
| Q4 25 | -19.9% | 25.3% | ||
| Q3 25 | -637.8% | 30.0% | ||
| Q2 25 | -203.3% | 29.2% | ||
| Q1 25 | -1077.2% | 28.4% | ||
| Q4 24 | -677.6% | 25.1% | ||
| Q3 24 | -785.4% | 28.6% | ||
| Q2 24 | -504.3% | 26.4% | ||
| Q1 24 | -408.0% | 27.4% |
每股收益（稀释后）ABCLZTS
| Q4 25 | $-0.03 | $1.37 | ||
| Q3 25 | $-0.19 | $1.63 | ||
| Q2 25 | $-0.12 | $1.61 | ||
| Q1 25 | $-0.15 | $1.41 | ||
| Q4 24 | $-0.11 | $1.29 | ||
| Q3 24 | $-0.17 | $1.50 | ||
| Q2 24 | $-0.13 | $1.37 | ||
| Q1 24 | $-0.14 | $1.31 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $128.5M | — |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $966.9M | $3.3B |
| 总资产 | $1.4B | $15.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ABCLZTS
| Q4 25 | $128.5M | — | ||
| Q3 25 | $83.2M | $2.1B | ||
| Q2 25 | $92.4M | $1.4B | ||
| Q1 25 | $159.3M | $1.7B | ||
| Q4 24 | $156.3M | $2.0B | ||
| Q3 24 | $126.6M | $1.7B | ||
| Q2 24 | $148.3M | $1.6B | ||
| Q1 24 | $123.6M | $2.0B |
股东权益ABCLZTS
| Q4 25 | $966.9M | $3.3B | ||
| Q3 25 | $964.0M | $5.4B | ||
| Q2 25 | $1.0B | $5.0B | ||
| Q1 25 | $1.0B | $4.7B | ||
| Q4 24 | $1.1B | $4.8B | ||
| Q3 24 | $1.1B | $5.2B | ||
| Q2 24 | $1.1B | $5.0B | ||
| Q1 24 | $1.1B | $5.1B |
总资产ABCLZTS
| Q4 25 | $1.4B | $15.5B | ||
| Q3 25 | $1.4B | $15.2B | ||
| Q2 25 | $1.4B | $14.5B | ||
| Q1 25 | $1.3B | $14.1B | ||
| Q4 24 | $1.4B | $14.2B | ||
| Q3 24 | $1.4B | $14.4B | ||
| Q2 24 | $1.4B | $14.2B | ||
| Q1 24 | $1.5B | $14.3B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-34.7M | $893.0M |
| 自由现金流经营现金流 - 资本支出 | $-44.6M | $732.0M |
| 自由现金流率自由现金流/营收 | -99.4% | 30.7% |
| 资本支出强度资本支出/营收 | 21.9% | 6.7% |
| 现金转化率经营现金流/净利润 | — | 1.48× |
| 过去12个月自由现金流最近4个季度 | $-174.1M | $2.3B |
8季度趋势，按日历期对齐
经营现金流ABCLZTS
| Q4 25 | $-34.7M | $893.0M | ||
| Q3 25 | $-52.6M | $938.0M | ||
| Q2 25 | $-32.4M | $486.0M | ||
| Q1 25 | $-11.6M | $587.0M | ||
| Q4 24 | $-8.0M | $905.0M | ||
| Q3 24 | $-28.9M | $951.0M | ||
| Q2 24 | $-30.0M | $502.0M | ||
| Q1 24 | $-41.7M | $595.0M |
自由现金流ABCLZTS
| Q4 25 | $-44.6M | $732.0M | ||
| Q3 25 | $-61.5M | $805.0M | ||
| Q2 25 | $-45.8M | $308.0M | ||
| Q1 25 | $-22.2M | $438.0M | ||
| Q4 24 | $-23.6M | $689.0M | ||
| Q3 24 | $-47.4M | $784.0M | ||
| Q2 24 | $-50.1M | $370.0M | ||
| Q1 24 | $-65.8M | $455.0M |
自由现金流率ABCLZTS
| Q4 25 | -99.4% | 30.7% | ||
| Q3 25 | -687.0% | 33.5% | ||
| Q2 25 | -267.9% | 12.5% | ||
| Q1 25 | -524.0% | 19.7% | ||
| Q4 24 | -468.0% | 29.7% | ||
| Q3 24 | -728.4% | 32.8% | ||
| Q2 24 | -683.8% | 15.7% | ||
| Q1 24 | -661.5% | 20.8% |
资本支出强度ABCLZTS
| Q4 25 | 21.9% | 6.7% | ||
| Q3 25 | 99.7% | 5.5% | ||
| Q2 25 | 78.2% | 7.2% | ||
| Q1 25 | 251.1% | 6.7% | ||
| Q4 24 | 309.6% | 9.3% | ||
| Q3 24 | 284.6% | 7.0% | ||
| Q2 24 | 274.6% | 5.6% | ||
| Q1 24 | 242.5% | 6.4% |
现金转化率ABCLZTS
| Q4 25 | — | 1.48× | ||
| Q3 25 | — | 1.30× | ||
| Q2 25 | — | 0.68× | ||
| Q1 25 | — | 0.93× | ||
| Q4 24 | — | 1.56× | ||
| Q3 24 | — | 1.39× | ||
| Q2 24 | — | 0.80× | ||
| Q1 24 | — | 0.99× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ABCL
暂无分部数据
ZTS
| Other | $1.3B | 56% |
| Livestock | $234.0M | 10% |
| Pain Sedation | $209.0M | 9% |
| Other Pharmaceuticals | $188.0M | 8% |
| Swine | $125.0M | 5% |
| Poultry | $117.0M | 5% |
| Fish | $81.0M | 3% |
| Other Non Pharmaceuticals | $70.0M | 3% |
| Manufactured Product Other | $18.0M | 1% |
| Medicated Feed Additives | $12.0M | 1% |
